Stay updated with breaking news from Cosara Diagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the...
Co-Diagnostics, Inc. (NASDAQ:CODX) Q2 2023 Earnings Call Transcript August 10, 2023 Co-Diagnostics, Inc. misses on earnings expectations. Reported EPS is $-0.31 EPS, expectations were $0.24. Operator: Welcome to the Co-Diagnostics Second Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask […]
The multiplex test is built on the company's patented CoPrimer technology
Co-Diagnostics turns 1Q net profit of nearly $8M on strong sales of its Logix Smart COVID-19 Test Fueled by $20 million in revenue, net income was $7.9 million as compared to a net loss of $1.1 million in the prior-year quarter Looking to the second quarter, Co-Diagnostics gave revenue guidance in the range of $20 million to $22 million Co-Diagnostics Inc (NASDAQ:CODX) reported that it earned a first-quarter net profit -- versus a loss last year -- on strong sales of its Logix Smart COVID-19 Test. For the quarter ended March 31, the company said income before taxes was $9.9 mill...
Share this article SALT LAKE CITY, May 13, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the first quarter ended March 31, 2021. First-Quarter 2021 Financial Results: Strong quarterly results highlighted by revenue of $20.0 million, pre-tax income of $9.9 million, diluted EPS of $0.26 Revenue of $20.0 million, primarily due to sales of the Logix Smart™ COVID-19 Test Gross profit increased to $16.8 million, representing 83.7...